XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · Real-Time Price · USD
1.600
-0.040 (-2.44%)
Nov 13, 2026, 4:00 PM EST - Market closed
XTL Biopharmaceuticals Employees
As of December 31, 2025, XTL Biopharmaceuticals had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees decreased by 5 or 50.00% compared to the previous year.
Employees
5
Change (1Y)
-5
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,393,800
Market Cap
5.66M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | -5 | -50.00% | 4 | 1 |
| Dec 31, 2024 | 10 | 3 | 42.86% | 10 | 0 |
| Dec 31, 2016 | 7 | 1 | 16.67% | 2 | 5 |
| Dec 31, 2015 | 6 | - | - | 3 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Cardio Diagnostics Holdings | 17 |
| Lantern Pharma | 16 |
| Processa Pharmaceuticals | 12 |
| Aprea Therapeutics | 8 |
| Alzamend Neuro | 6 |
| Cadrenal Therapeutics | 5 |
| Tempest Therapeutics | 4 |
XTLB News
- 4 months ago - XTL BioPharma Closes Acquisition Of Psyga Bio; Shifts Focus To Psychedelic Therapies - Nasdaq
- 4 months ago - XTL Completed the Acquisition of Psyga Bio Ltd. - GlobeNewsWire
- 5 months ago - XTL Announces Receipt of Staff Delist Determination from Nasdaq - GlobeNewsWire
- 6 months ago - 3 Penny Stocks to Watch Now, 4/30/26 - TipRanks
- 6 months ago - XTL Biopharmaceuticals to acquire Psyga Bio - TheFly
- 6 months ago - XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies - GlobeNewsWire
- 7 months ago - XTL Biopharmaceuticals trading halted, news pending - TheFly
- 7 months ago - XTL Biopharmaceuticals announces ADS ratio change - TheFly